James R. Falsey
Amgen (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Receptor Mechanisms and Signaling, Catalytic C–H Functionalization Methods, Diabetes Treatment and Management, Neuropeptides and Animal Physiology
Most-Cited Works
- → Peptide and Small Molecule Microarray for High Throughput Cell Adhesion and Functional Assays(2001)324 cited
- → A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings(2024)168 cited
- → Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism(2020)131 cited
- → Novel Vanilloid Receptor-1 Antagonists: 2. Structure−Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate(2007)98 cited
- → GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys(2021)81 cited
- → Palladium-Catalyzed Chemoselective Monoarylation of Hydrazides for the Synthesis of [1,2,4]Triazolo[4,3-a]pyridines(2010)78 cited
- → Discovery of Highly Selective and Potent p38 Inhibitors Based on a Phthalazine Scaffold(2008)58 cited
- → Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors(2012)37 cited
- → N-substituted azaindoles as potent inhibitors of Cdc7 kinase(2013)37 cited
- → Engineering Antibody Reactivity for Efficient Derivatization to Generate NaV1.7 Inhibitory GpTx-1 Peptide–Antibody Conjugates(2017)28 cited